Funding

Dublin-based SynOx raises $75m in development of rare tumour-busting antibody

Latest raise is to be used for Phase 3 clinical data for Emactuzumab - which is used in the treatment of Tenosynovial Giant Cell Tumours

TGCT is a type of tumour that affects the soft tissue lining of joints and tendons and is a highly debilitating disease. Picture: Getty

SynOx Therapeutics, a Dublin-headquartered late-stage clinical biopharmaceutical company, has raised $75 million (€70.4 million) in funding to continue the development of Emactuzumab, an antibody that targets tumours.

SynOx was founded in 2020 after securing worldwide rights to develop Emactuzumab under a licence agreement with Roche. The firm previously raised $37 million in a Series A funding round.

The latest raise is to be used for Phase 3 clinical data for the solution, which is used in ...